Orum Therapeutics Inc

Akashi Therapeutics, based in Cambridge, is a global biopharmaceutical company with a focus on developing innovative therapies for individuals affected by rare disorders. The company's mission is to create life-changing treatments that address the unmet medical needs of those living with rare diseases, aiming to improve the quality of life for patients worldwide. Generated from their website's infomation

Morphic Therapeutic Inc is a pioneering biopharmaceutical company based in Waltham, MA, specializing in the development of oral integrin medicines. Leveraging their extensive expertise in integrin biology, they aim to transform treatment paradigms for patients across multiple therapeutic areas, including autoimmune diseases, fibrosis diseases, and cancer. Their lead candidate, MORF-057, is a highly specific inhibitor of 4 7 currently in Phase 2 for inflammatory bowel disease (IBD). With a pipeline that encompasses both novel and highly validated targets, Morphic Therapeutic is committed to drugging integrins through small molecules to address unmet medical needs. They have also established a research partnership with Janssen to discover inhibitors of undisclosed integrin targets, expanding their knowledge of integrin biology into modalities beyond small molecules. Additionally, Morphic is actively developing small molecule inhibitors for the treatment of pulmonary arterial hypertension (PAH), solid tumors, and other indications, utilizing their MInT Platform to create therapeutically relevant compounds with enhanced attributes.Generated from the website

Thiogenesis Therapeutics, Inc is a biotechnology company based in Belmont, MA, dedicated to advancing research and development in the field of therapeutic solutions. Specializing in innovative approaches to address complex medical challenges, the company focuses on creating novel treatments with the potential to improve patient outcomes. Generated from their business information